Nephrology News
FDA Approves Cabometyx for First-Line Treatment of Advanced RCC
Treatment with cabozantinib led to a clinically meaningful improvement in progression-free survival compared with sunitinib.
By accepting you will be accessing a service provided by a third-party external to https://galencarepartners.com/